Allena Pharmaceuticals Inc logo

ALNA - Allena Pharmaceuticals Inc Share Price

$2.54 -0.0  -0.8%

Last Trade - 4:44pm

Sector
Healthcare
Size
Micro Cap
Market Cap £46.0m
Enterprise Value £23.5m
Revenue £n/a
Position in Universe 4615th / 6416
Bullish
Bearish
Unlock ALNA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALNA Revenue Unlock ALNA Revenue

Net Income

ALNA Net Income Unlock ALNA Revenue

Normalised EPS

ALNA Normalised EPS Unlock ALNA Revenue

PE Ratio Range

ALNA PE Ratio Range Unlock ALNA Revenue

Dividend Yield Range

ALNA Dividend Yield Range Unlock ALNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALNA EPS Forecasts Unlock ALNA Revenue
Profile Summary

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated June 24, 2011
Public Since November 2, 2017
No. of Shareholders: 22
No. of Employees: 45
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 23,465,665
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALNA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALNA
Upcoming Events for ALNA
Similar to ALNA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.